News Analysis: AI offers new route to cancer vaccines, but hurdles remain - Xinhua

LONDON, Oct. 16 (Xinhua) -- British researchers are bringing artificial intelligence (AI), automated laboratories and supercomputing together to accelerate the development of personalized cancer vaccines. The effort aims to test whether a more connected research process can shorten the journey from identifying a tumor target to treating a patient. The University of Oxford announced early this month that the Advanced Research and Invention Agency (ARIA) was providing an additional 8 million pounds (about 10.6 million U. S. dollars) for the university's UK Cancer Vaccine AI Scientist and Supercomputing Project. The project combines AI tools for selecting vaccine targets with automated laboratory experiments and data analysis, under the guidance of oncologists. "AI gives us an extraordinary opportunity to find vaccine targets faster and learn from every experiment," said Dr Lennard Lee at Oxford's Center for Immuno-Oncology. Personalized cancer vaccines aim to direct a patient's immune system against their tumor. A central challenge is identifying tumor fragments that will trigger an effective immune response.

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.